iBio: Kooperation mit Fraunhofer - ws geht da ab? - 500 Beiträge pro Seite
eröffnet am 17.08.10 18:44:23 von
neuester Beitrag 16.03.11 20:48:47 von
neuester Beitrag 16.03.11 20:48:47 von
Beiträge: 30
ID: 1.159.399
ID: 1.159.399
Aufrufe heute: 0
Gesamt: 854
Gesamt: 854
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 1 Stunde | 4300 | |
| vor 1 Stunde | 2220 | |
| vor 42 Minuten | 2001 | |
| 01.05.24, 18:36 | 1656 | |
| heute 09:48 | 956 | |
| vor 52 Minuten | 865 | |
| vor 1 Stunde | 755 | |
| vor 38 Minuten | 742 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 2. | 18.168,87 | +0,81 | 167 | |||
| 2. | 1. | 170,26 | +1,22 | 88 | |||
| 3. | 9. | 10,320 | +6,39 | 33 | |||
| 4. | 3. | 0,1975 | +5,90 | 28 | |||
| 5. | 4. | 2.319,46 | +0,77 | 23 | |||
| 6. | 10. | 0,9750 | +11,43 | 21 | |||
| 7. | 5. | 0,1709 | +9,48 | 21 | |||
| 8. | 6. | 0,0793 | +15,09 | 20 |
Feedback
Im Biotech-Sektor stoß ich immer wieder mal auf diese iBio Inc.
Die machten eine Kooperation mit unserem deutschen Fraunhofer Institut.
Ich find eine Studie von NobleFinance, die ein Kursziel von 4 $ ausgibt. Vor allem wegen der Koop mit Fraunhofer.
Weiß da jemand mehr drüber? Ich kann das irgendwie nicht so richtig einschätzen. Aber es klingt irgendwie hochspannend.
iBio hat noch keine hiesige WKN. Aber mit 49 Mio. $ Mkap sollte sich doch was machen lassen.
Die machten eine Kooperation mit unserem deutschen Fraunhofer Institut.
Ich find eine Studie von NobleFinance, die ein Kursziel von 4 $ ausgibt. Vor allem wegen der Koop mit Fraunhofer.
Weiß da jemand mehr drüber? Ich kann das irgendwie nicht so richtig einschätzen. Aber es klingt irgendwie hochspannend.
iBio hat noch keine hiesige WKN. Aber mit 49 Mio. $ Mkap sollte sich doch was machen lassen.
Antwort auf Beitrag Nr.: 39.999.675 von wertsteigerung am 17.08.10 18:44:23
"Die machten eine Kooperation mit unserem deutschen Fraunhofer Institut.
Ich find eine Studie von NobleFinance, die ein Kursziel von 4 $ ausgibt. Vor allem wegen der Koop mit Fraunhofer."
Machen oder machten? Wo ist diese besagte Recherche -dann könnte man da sogar mal reingucken.
Gruß
P.
"Die machten eine Kooperation mit unserem deutschen Fraunhofer Institut.
Ich find eine Studie von NobleFinance, die ein Kursziel von 4 $ ausgibt. Vor allem wegen der Koop mit Fraunhofer."
Machen oder machten? Wo ist diese besagte Recherche -dann könnte man da sogar mal reingucken.
Gruß
P.
Antwort auf Beitrag Nr.: 40.003.443 von Popeye82 am 18.08.10 10:54:52
iBio and Fraunhofer USA Center for Molecular Biotechnology Enter Agreement to Provide Global Access for Bill & Melinda Gates Foundation Vaccines
.
Companies:iBio, Inc..Related Quotes
Symbol Price Change
IBPM.OB 1.76 0.00
{"s" : "ibpm.ob","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""} Press Release Source: iBio, Inc. On Thursday June 3, 2010, 8:30 am EDT
NEWARK, Del.--(BUSINESS WIRE)--iBio, Inc. (OTCBB: IBPM - News) and the Fraunhofer USA Center for Molecular Biotechnology (CMB) announced today an agreement which provides a license of iBio’s proprietary technology to CMB for the development and manufacture of Global Health Vaccines for, and financed by, the Bill & Melinda Gates Foundation.
As recently announced, a principal focus of the Bill & Melinda Gates Foundation is to provide access to vaccines for the neediest people in the developing countries in the world (Global Alliance for Vaccines & Immunization (GAVI) Eligible Countries), representing vast numbers of people currently unable to afford preventive and therapeutic medical care (Global Access Objectives). Global Health Vaccines, subject to this agreement, are vaccines for human or veterinary use for the prevention of malaria, tuberculosis, rotavirus, trypanosomiasis, hookworm and rabies.
Under the terms of the Agreement, CMB will use iBio’s technology under a non-exclusive, non-royalty bearing grant to develop and test new Global Health Vaccines funded by the Bill & Melinda Gates Foundation. The Agreement establishes iBio as the preferred manufacturer of Global Health Vaccines and provides a right of first refusal to iBio to provide technology transfer and vaccine manufacturing services to achieve Global Access Objectives on a commercially reasonable, competitive and sustainable cost basis. In accordance with prior agreements, iBio will own commercial rights to new technology and improvements arising during the course of the programs. Additional terms of the Agreement provide for mutual cooperation with respect to the sharing of clinical data and regulatory filings related to the program.
“The attributes of our technology – including rapid response to pandemic disease threats, surge capacity, and scalable manufacturing facilities with much lower capital and operating costs – should enable the Foundation to achieve its objective to provide vaccines to vast populations that have been neglected until now,” said Robert Kay, Chairman and Chief Executive Officer of iBio. “In this symbiotic relationship, as we help the Foundation achieve its Foundation-funded Global Access Objectives, iBio is helped to optimize and broaden its technology platform for commercial purposes and expand its commercial manufacturing and tech transfer programs.”
“This agreement is an important step in advancing this powerful technology to serve people often bypassed by important medical advances and new technologies,” said Major General (ret.) Philip K. Russell, M.D., advisor to the Bill & Melinda Gates Foundation and member of the iBio Board of Directors. “Our experience with this technology in challenging vaccine applications gives us great optimism about practical utility.”
“The Bill & Melinda Gates Foundation and iBio, along with the Defense Advanced Research Projects Agency (DARPA), are key stakeholders in the success of our technology development. Their support was critical for establishing this technology and demonstrating its potential for development of vaccines against viral, bacterial and parasitic diseases,” said Dr. Vidadi Yusibov, Executive Director of CMB and Chief Scientific Officer of iBio. “I am confident this cooperation will provide great benefit for all parties.”
About iBio, Inc.
iBio, Inc. is a biopharmaceutical company commercializing its proprietary technology, the iBioLaunch
iBio and Fraunhofer USA Center for Molecular Biotechnology Enter Agreement to Provide Global Access for Bill & Melinda Gates Foundation Vaccines
.
Companies:iBio, Inc..Related Quotes
Symbol Price Change
IBPM.OB 1.76 0.00
{"s" : "ibpm.ob","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""} Press Release Source: iBio, Inc. On Thursday June 3, 2010, 8:30 am EDT
NEWARK, Del.--(BUSINESS WIRE)--iBio, Inc. (OTCBB: IBPM - News) and the Fraunhofer USA Center for Molecular Biotechnology (CMB) announced today an agreement which provides a license of iBio’s proprietary technology to CMB for the development and manufacture of Global Health Vaccines for, and financed by, the Bill & Melinda Gates Foundation.
As recently announced, a principal focus of the Bill & Melinda Gates Foundation is to provide access to vaccines for the neediest people in the developing countries in the world (Global Alliance for Vaccines & Immunization (GAVI) Eligible Countries), representing vast numbers of people currently unable to afford preventive and therapeutic medical care (Global Access Objectives). Global Health Vaccines, subject to this agreement, are vaccines for human or veterinary use for the prevention of malaria, tuberculosis, rotavirus, trypanosomiasis, hookworm and rabies.
Under the terms of the Agreement, CMB will use iBio’s technology under a non-exclusive, non-royalty bearing grant to develop and test new Global Health Vaccines funded by the Bill & Melinda Gates Foundation. The Agreement establishes iBio as the preferred manufacturer of Global Health Vaccines and provides a right of first refusal to iBio to provide technology transfer and vaccine manufacturing services to achieve Global Access Objectives on a commercially reasonable, competitive and sustainable cost basis. In accordance with prior agreements, iBio will own commercial rights to new technology and improvements arising during the course of the programs. Additional terms of the Agreement provide for mutual cooperation with respect to the sharing of clinical data and regulatory filings related to the program.
“The attributes of our technology – including rapid response to pandemic disease threats, surge capacity, and scalable manufacturing facilities with much lower capital and operating costs – should enable the Foundation to achieve its objective to provide vaccines to vast populations that have been neglected until now,” said Robert Kay, Chairman and Chief Executive Officer of iBio. “In this symbiotic relationship, as we help the Foundation achieve its Foundation-funded Global Access Objectives, iBio is helped to optimize and broaden its technology platform for commercial purposes and expand its commercial manufacturing and tech transfer programs.”
“This agreement is an important step in advancing this powerful technology to serve people often bypassed by important medical advances and new technologies,” said Major General (ret.) Philip K. Russell, M.D., advisor to the Bill & Melinda Gates Foundation and member of the iBio Board of Directors. “Our experience with this technology in challenging vaccine applications gives us great optimism about practical utility.”
“The Bill & Melinda Gates Foundation and iBio, along with the Defense Advanced Research Projects Agency (DARPA), are key stakeholders in the success of our technology development. Their support was critical for establishing this technology and demonstrating its potential for development of vaccines against viral, bacterial and parasitic diseases,” said Dr. Vidadi Yusibov, Executive Director of CMB and Chief Scientific Officer of iBio. “I am confident this cooperation will provide great benefit for all parties.”
About iBio, Inc.
iBio, Inc. is a biopharmaceutical company commercializing its proprietary technology, the iBioLaunch
Ich sehe die Aktie bis Mitte Septemer 2010 bei 2,50 US$ und an der AMEX sowie in Deutschland gelistet!!!!
Antwort auf Beitrag Nr.: 40.011.177 von birdie4711 am 19.08.10 11:01:14und wer sich genau informieren will geht auf die schweizer webseitehttp://www.globemedia.ch/
Trading Spotlight
Antwort auf Beitrag Nr.: 40.003.443 von Popeye82 am 18.08.10 10:54:52Ich habe noch etwas gefunden für dich!!!
: Q: iBio vs. Fraunhofer royalties no response 26-Jun-10 10:27 am I jumped the gun, and I am happy to report that iBio's president, Mr. Bob Erwin, did respond later in the day (text at the end), and it appears that I got it backwards in that it is iBio which will be the major beneficiary of the human therapeutic royalties (splitting it 85% / 15%) with Fraunhofer and for other industrial applications the split is 9% /91 % in favor of Fraunhofer.
Following is the text of Bob Erwin's response:
"iBio owns the technology and has exclusive global rights to all human healthcare and some veterinary applications. We have licensed the technology back to Fraunhofer for other potential applications.
Our agreement with Fraunhofer provides for iBio to pay Fraunhofer 1% of all receipts derived by us from sales of products utilizing the proprietary technology and 15% of all receipts derived by us from licensing the proprietary technology to third parties. Our agreement provides for Fraunhofer to pay iBio royalty payments equal to 9% of all receipts realized by Fraunhofer, if any, from sales, licensing, or commercialization of the intellectual property licensed from us
: Q: iBio vs. Fraunhofer royalties no response 26-Jun-10 10:27 am I jumped the gun, and I am happy to report that iBio's president, Mr. Bob Erwin, did respond later in the day (text at the end), and it appears that I got it backwards in that it is iBio which will be the major beneficiary of the human therapeutic royalties (splitting it 85% / 15%) with Fraunhofer and for other industrial applications the split is 9% /91 % in favor of Fraunhofer.
Following is the text of Bob Erwin's response:
"iBio owns the technology and has exclusive global rights to all human healthcare and some veterinary applications. We have licensed the technology back to Fraunhofer for other potential applications.
Our agreement with Fraunhofer provides for iBio to pay Fraunhofer 1% of all receipts derived by us from sales of products utilizing the proprietary technology and 15% of all receipts derived by us from licensing the proprietary technology to third parties. Our agreement provides for Fraunhofer to pay iBio royalty payments equal to 9% of all receipts realized by Fraunhofer, if any, from sales, licensing, or commercialization of the intellectual property licensed from us
wenn ihr die Aktie in real-time verfolgen wollt hier ist der link!!!!!!!
http://www.otcmarkets.com/stock/ibpm/quote viel Spaß !!!
http://www.otcmarkets.com/stock/ibpm/quote viel Spaß !!!
Antwort auf Beitrag Nr.: 40.012.015 von birdie4711 am 19.08.10 12:30:52habe was gekauft, Danke für deine Ausführungen und links!!! hoffentlich sehen wir 2,50 $
Antwort auf Beitrag Nr.: 40.015.397 von kfz am 19.08.10 18:09:58trotz des schwachen Umfeldes gestern eine leicht Steigerung der Aktie
Antwort auf Beitrag Nr.: 40.017.928 von birdie4711 am 20.08.10 08:04:45Eine Aktie die man beachten sollte
PRICES
Date Open High Low Close Volume Adj Close*
Aug 19, 2010 1.78 1.82 1.77 1.78 41,100 1.78
Aug 18, 2010 1.74 1.78 1.73 1.76 42,100 1.76
Aug 17, 2010 1.73 1.74 1.72 1.73 14,600 1.73
Aug 16, 2010 1.70 1.73 1.70 1.73 10,500 1.73
Aug 13, 2010 1.66 1.70 1.66 1.69 8,500 1.69
Aug 12, 2010 1.65 1.69 1.65 1.69 9,400 1.69
Aug 11, 2010 1.65 1.65 1.65 1.65 4,300 1.65
Aug 10, 2010 1.66 1.66 1.45 1.65 30,600 1.65
Aug 9, 2010 1.69 1.69 1.67 1.67 1,400 1.67
Aug 6, 2010 1.67 1.67 1.66 1.67 11,200 1.67
Aug 5, 2010 1.65 1.66 1.65 1.66 9,800 1.66
Aug 4, 2010 1.67 1.67 1.63 1.66 35,600 1.66
Aug 3, 2010 1.65 1.65 1.65 1.65 3,800 1.65
Aug 2, 2010 1.62 1.66 1.60 1.65 25,200 1.65
Jul 30, 2010 1.63 1.63 1.62 1.62 11,900 1.62
Jul 29, 2010 1.63 1.63 1.59 1.61 12,800 1.61
Jul 28, 2010 1.61 1.62 1.55 1.62 16,300 1.62
Jul 27, 2010 1.59 1.61 1.50 1.61 39,600 1.61
Jul 26, 2010 1.60 1.60 1.50 1.55 23,400 1.55
Jul 23, 2010 1.46 1.60 1.46 1.58 38,000 1.58
PRICES
Date Open High Low Close Volume Adj Close*
Aug 19, 2010 1.78 1.82 1.77 1.78 41,100 1.78
Aug 18, 2010 1.74 1.78 1.73 1.76 42,100 1.76
Aug 17, 2010 1.73 1.74 1.72 1.73 14,600 1.73
Aug 16, 2010 1.70 1.73 1.70 1.73 10,500 1.73
Aug 13, 2010 1.66 1.70 1.66 1.69 8,500 1.69
Aug 12, 2010 1.65 1.69 1.65 1.69 9,400 1.69
Aug 11, 2010 1.65 1.65 1.65 1.65 4,300 1.65
Aug 10, 2010 1.66 1.66 1.45 1.65 30,600 1.65
Aug 9, 2010 1.69 1.69 1.67 1.67 1,400 1.67
Aug 6, 2010 1.67 1.67 1.66 1.67 11,200 1.67
Aug 5, 2010 1.65 1.66 1.65 1.66 9,800 1.66
Aug 4, 2010 1.67 1.67 1.63 1.66 35,600 1.66
Aug 3, 2010 1.65 1.65 1.65 1.65 3,800 1.65
Aug 2, 2010 1.62 1.66 1.60 1.65 25,200 1.65
Jul 30, 2010 1.63 1.63 1.62 1.62 11,900 1.62
Jul 29, 2010 1.63 1.63 1.59 1.61 12,800 1.61
Jul 28, 2010 1.61 1.62 1.55 1.62 16,300 1.62
Jul 27, 2010 1.59 1.61 1.50 1.61 39,600 1.61
Jul 26, 2010 1.60 1.60 1.50 1.55 23,400 1.55
Jul 23, 2010 1.46 1.60 1.46 1.58 38,000 1.58
wollen mal sehen was heute noch passiert??
Antwort auf Beitrag Nr.: 40.021.010 von birdie4711 am 20.08.10 15:31:05I´m feeling good !!!! higher volume und der Aktienpreis im grünen Bereich
IBIO Pharma ist jetzt auch in Berlin gelistet!!!!!
1,490 EUR Vortag Eröff. Tag 52-Wochen letztes gesamt
+0,06 +4,20% 1,430 1,490 1,490 1,490 1,430 1,430 n.a. n.a.
jetzt
1,490 EUR Vortag Eröff. Tag 52-Wochen letztes gesamt
+0,06 +4,20% 1,430 1,490 1,490 1,490 1,430 1,430 n.a. n.a.
jetzt
Antwort auf Beitrag Nr.: 40.033.758 von birdie4711 am 24.08.10 09:32:30bitte beachten Kursziel 12 Monate 4.00, 2 Monate 2.50 US Dollar
Antwort auf Beitrag Nr.: 40.043.450 von birdie4711 am 25.08.10 15:43:38heute plus 1,08 % nicht schlecht für die paar Minuten trading!!
Antwort auf Beitrag Nr.: 40.043.553 von birdie4711 am 25.08.10 15:57:09
1,97 US-Doller
Zwischenzeitlich sind wir unbemerkt bei 2,20 !!
Antwort auf Beitrag Nr.: 40.140.449 von kfz am 13.09.10 11:43:03Aktie steigt auf 2.39 und gutes Volumen Einfach dabeibleiben!!!
Einfach dabeibleiben!!!
Wuhh, hat sich gut gemacht in USA.
3,30 $ gerade gehandelt.
Aber immer noch OTC. Nix Amex oder Deutschland gelistet.
Kommt das noch?
3,30 $ gerade gehandelt.
Aber immer noch OTC. Nix Amex oder Deutschland gelistet.
Kommt das noch?
was sagt Ihr zu meiner Empfehlung!!!
Was sagt Ihr zu meiner Empfehlung !!!!
Ist jetzt Amex 3,80 U$
Ist jetzt Amex gelistet 3,80 U$
Jetzt 4,91 US$
mit 350% Gewinn beende ich hiermit die Diskussion!!!!
mit 350% Gewinn beende ich hiermit die Diskussion!!!!
Es ist schon toll mit dieser Kiste gestern über 6$, investiere nun in
N e u r a l s t e m auch gelistet in Frankfurt!!!! und nun endgültig
Ade IBIO
N e u r a l s t e m auch gelistet in Frankfurt!!!! und nun endgültig
Ade IBIO
iBio(AMEX: IBIO )Feiner turnaround schon seit Tagen.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 167 | ||
| 88 | ||
| 33 | ||
| 28 | ||
| 23 | ||
| 21 | ||
| 21 | ||
| 20 | ||
| 16 | ||
| 14 |
| Wertpapier | Beiträge | |
|---|---|---|
| 13 | ||
| 12 | ||
| 10 | ||
| 9 | ||
| 9 | ||
| 9 | ||
| 8 | ||
| 8 | ||
| 7 | ||
| 7 |
